SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cell Therapeutics, Inc. Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers